BTG receives CE mark certification for radiopaque drug-eluting bead
European Pharmaceutical Review | April 06, 2017
BTG, a global specialist healthcare company, has received Class III CE Mark certification for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead (DEB) in the EU which can be loaded with doxorubicin or irinotecan.